Prices delayed by at least 15 minutes | Print
United Therapeutics Corp (UTHR)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus onthe prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Address
1040 Spring Street
Silver Spring
MD
USA
20910
Telephone
+1 202 9194097
Forecast key dates
Name | Key Date |
---|---|
United Therapeutics Corp Fourth Quarter Earnings Conference Call for 2024 | 2025-02-21T09:00:00 |
United Therapeutics Corp Fourth Quarter Earnings Results for 2024 | 2025-02-21T00:00:00 |
United Therapeutics Corp Annual Report for 2024 | 2025-02-21T00:00:00 |
United Therapeutics Corp Third Quarter Earnings Conference Call for 2024 | 2024-11-01T09:00:00 |
United Therapeutics Corp Third Quarter Earnings Results for 2024 | 2024-11-01T00:00:00 |
United Therapeutics Corp Second Quarter Earnings Conference Call for 2024 | 2024-08-02T09:00:00 |
United Therapeutics Corp Second Quarter Earnings Results for 2024 | 2024-08-02T00:00:00 |
United Therapeutics Corp Annual General Meeting for 2024 | 2024-06-26T10:30:00 |
United Therapeutics Corp First Quarter Earnings Conference Call for 2024 | 2024-05-01T09:00:00 |
United Therapeutics Corp First Quarter Earnings Results for 2024 | 2024-05-01T06:30:00 |
Previous key dates
Name | Key Date |
---|---|
the Leerink Partners Global Biopharma Conference | 2024-03-12T13:40:00 |
TD Cowen 44th Annual Health Care Conference 2024 | 2024-03-05T12:50:00 |
United Therapeutics Corp Fourth Quarter Earnings Conference Call for 2023 | 2024-02-21T09:00:00 |
United Therapeutics Corp Fourth Quarter Earnings Result for 2023 | 2024-02-21T00:00:00 |
United Therapeutics Corp Annual Report for 2023 | 2024-02-21T00:00:00 |
United Therapeutics Corp Third Quarter Earnings Conference Call for 2023 | 2023-11-01T09:00:00 |
United Therapeutics Corp Third Quarter Earnings Result for 2023 | 2023-11-01T00:00:00 |
United Therapeutics Corp Second Quarter Earnings Conference Call for 2023 | 2023-08-02T09:00:00 |
United Therapeutics Corp Second Quarter Earnings Result for 2023 | 2023-08-02T00:00:00 |
United Therapeutics Corp Annual General Meeting for 2023 | 2023-06-26T10:30:00 |
United Therapeutics Corp First Quarter Earnings Conference Call for 2023 | 2023-05-03T09:00:00 |
United Therapeutics Corp First Quarter Earnings Result for 2023 | 2023-05-03T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.